Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YE-NEO-001 in Previously Treated Cancers
NCT03552718Phase 1Completed
- Sponsor
- NantBioScience
- Start
- Aug 2018
- Primary completion
- Mar 2025
- Modality
- Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of YE-NEO-001 in colorectal cancer (CRC), breast cancer, head and neck squamous cell carcinoma (HNSCC) and 4 more, sponsored by NantBioScience. Primary endpoints: Incidence of treatment-emergent adverse events at 19 months and Recommended Phase 2 Dose at 19 months. Started Aug 2018; status: completed.
02
Drugs
YE-NEO-001
03
Conditions
colorectal cancer (CRC)breast cancerhead and neck squamous cell carcinoma (HNSCC)melanomanon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03552718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03552718.